Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study

BACKGROUND: Immune checkpoint blockade (ICB) has led to a growing population of long-term advanced cancer survivors. However, data on neurocognitive functioning (NCF) and psychological outcomes after ICB remain limited, particularly from longitudinal studies incorporating control groups. METHODS: In this prospective longitudinal study, cancer survivors who had ICB-treated, unresectable, stage III-IV disease completed neuropsychological testing and patient-reported outcome measures (PROMs) at baseline and at 6-month and 18-month follow-up. Objective NCF was compared with healthy matched controls. Linear mixed models evaluated longitudinal changes, and correlation analyses examined associations between NCF and PROMs. RESULTS: Of the 112 eligible patients, 79 were included. The median time since ICB initiation was 5.3 years. Compared with matched controls, survivors demonstrated poorer performance in learning and long-term memory. Objective neurocognitive test performance improved over time, with the prevalence of neurocognitive impairment decreasing from 49% to 27%. Subjective cognitive complaints affected 20% of survivors, remained stable, and were strongly associated with anxiety, depressive symptoms, fatigue, post-traumatic stress disorder, fear of cancer recurrence, and poorer quality of life, but not with objective NCF. Significant fear of cancer recurrence affected 53% of survivors, including 22% with pathologic levels, and persisted over time. Fatigue, anxiety, depressive symptoms, and post-traumatic stress disorder symptoms were also prevalent and stable throughout follow-up. CONCLUSIONS: Survivors who received treatment with ICB demonstrated poorer neurocognitive test performance than healthy matched controls, particularly in learning and memory, but showed gradual improvement over time. In contrast, psychological symptoms, especially fear of cancer recurrence, persisted. These findings support routine survivorship screening, timely referral to interventions for fear of cancer recurrence, and integrative management of cognitive and psychological symptoms.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-11-18
DOI
https://doi.org/10.1002/cncr.70668
Primary Topic
Cancer-related cognitive impairment studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study

Cristina Delgado‐Alonso, Anne Rogiers, Cleo Bertels, Nathalie Vanlaer et al.
5 links
Cancer
Cancer-related cognitive impairment studies
article

Neurocognitive functioning and psychological outcomes in advanced cancer survivors treated with immune checkpoint blockade: A prospective longitudinal study

Cristina Delgado‐Alonso, Anne Rogiers, Cleo Bertels, Nathalie Vanlaer, Iris Dirven, Bart Neyns, Jordi A. Matías‐Guiu
article en

Abstract

BACKGROUND: Immune checkpoint blockade (ICB) has led to a growing population of long-term advanced cancer survivors. However, data on neurocognitive functioning (NCF) and psychological outcomes after ICB remain limited, particularly from longitudinal studies incorporating control groups. METHODS: In this prospective longitudinal study, cancer survivors who had ICB-treated, unresectable, stage III-IV disease completed neuropsychological testing and patient-reported outcome measures (PROMs) at baseline and at 6-month and 18-month follow-up. Objective NCF was compared with healthy matched controls. Linear mixed models evaluated longitudinal changes, and correlation analyses examined associations between NCF and PROMs. RESULTS: Of the 112 eligible patients, 79 were included. The median time since ICB initiation was 5.3 years. Compared with matched controls, survivors demonstrated poorer performance in learning and long-term memory. Objective neurocognitive test performance improved over time, with the prevalence of neurocognitive impairment decreasing from 49% to 27%. Subjective cognitive complaints affected 20% of survivors, remained stable, and were strongly associated with anxiety, depressive symptoms, fatigue, post-traumatic stress disorder, fear of cancer recurrence, and poorer quality of life, but not with objective NCF. Significant fear of cancer recurrence affected 53% of survivors, including 22% with pathologic levels, and persisted over time. Fatigue, anxiety, depressive symptoms, and post-traumatic stress disorder symptoms were also prevalent and stable throughout follow-up. CONCLUSIONS: Survivors who received treatment with ICB demonstrated poorer neurocognitive test performance than healthy matched controls, particularly in learning and memory, but showed gradual improvement over time. In contrast, psychological symptoms, especially fear of cancer recurrence, persisted. These findings support routine survivorship screening, timely referral to interventions for fear of cancer recurrence, and integrative management of cognitive and psychological symptoms.

CancerVol. 132(23)
Universidad Complutense de Madrid (ES), Vrije Universiteit Brussel (BE), Hospital Clínico San Carlos (ES), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Centre Hospitalier Universitaire Brugmann (BE), Universitair Ziekenhuis Brussel (BE)
Fonds Wetenschappelijk Onderzoek
Good health and well-being
Cancer-related cognitive impairment studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon